Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Change in Cash: 2023-2025

Historic Change in Cash for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $128.8 million.

  • Immunome's Change in Cash rose 1418.75% to $128.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.2 million, marking a year-over-year increase of 80.48%. This contributed to the annual value of $44.7 million for FY2024, which is 42.99% down from last year.
  • According to the latest figures from Q3 2025, Immunome's Change in Cash is $128.8 million, which was up 213.32% from -$113.6 million recorded in Q2 2025.
  • Over the past 5 years, Immunome's Change in Cash peaked at $171.0 million during Q1 2024, and registered a low of -$113.6 million during Q2 2025.
  • In the last 3 years, Immunome's Change in Cash had a median value of $8.0 million in 2023 and averaged $22.9 million.
  • Its Change in Cash has fluctuated over the past 5 years, first crashed by 1,637.53% in 2024, then skyrocketed by 1,418.75% in 2025.
  • Quarterly analysis of 3 years shows Immunome's Change in Cash stood at $8.0 million in 2023, then slumped by 251.99% to -$12.2 million in 2024, then soared by 1,418.75% to $128.8 million in 2025.
  • Its last three reported values are $128.8 million in Q3 2025, -$113.6 million for Q2 2025, and $114.3 million during Q1 2025.